CL2023000296A1 - Uso de dexpramipexol para el tratamiento del asma moderado a grave - Google Patents

Uso de dexpramipexol para el tratamiento del asma moderado a grave

Info

Publication number
CL2023000296A1
CL2023000296A1 CL2023000296A CL2023000296A CL2023000296A1 CL 2023000296 A1 CL2023000296 A1 CL 2023000296A1 CL 2023000296 A CL2023000296 A CL 2023000296A CL 2023000296 A CL2023000296 A CL 2023000296A CL 2023000296 A1 CL2023000296 A1 CL 2023000296A1
Authority
CL
Chile
Prior art keywords
dexpramipexole
severe asthma
moderate
treatment
pharmaceutically acceptable
Prior art date
Application number
CL2023000296A
Other languages
English (en)
Spanish (es)
Inventor
Philip Prussin Calman
Original Assignee
Areteia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Areteia Therapeutics Inc filed Critical Areteia Therapeutics Inc
Publication of CL2023000296A1 publication Critical patent/CL2023000296A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2023000296A 2020-08-05 2023-01-30 Uso de dexpramipexol para el tratamiento del asma moderado a grave CL2023000296A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063061226P 2020-08-05 2020-08-05
US202163136933P 2021-01-13 2021-01-13
US202163147024P 2021-02-08 2021-02-08
US202163174938P 2021-04-14 2021-04-14

Publications (1)

Publication Number Publication Date
CL2023000296A1 true CL2023000296A1 (es) 2023-08-25

Family

ID=80115688

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000296A CL2023000296A1 (es) 2020-08-05 2023-01-30 Uso de dexpramipexol para el tratamiento del asma moderado a grave

Country Status (11)

Country Link
US (4) US20220040154A1 (enExample)
EP (1) EP4192453A4 (enExample)
JP (1) JP2023538278A (enExample)
KR (1) KR20230067604A (enExample)
CN (1) CN116419746A (enExample)
AU (1) AU2021322255A1 (enExample)
CA (1) CA3186844A1 (enExample)
CL (1) CL2023000296A1 (enExample)
IL (1) IL300357A (enExample)
MX (1) MX2023001140A (enExample)
WO (1) WO2022031956A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260119B (zh) * 2022-07-26 2023-02-10 山东京卫制药有限公司 一种普拉克索昔萘酸盐及其药物缓释制剂
KR102985795B1 (ko) 2023-06-29 2026-07-06 재단법인 아산사회복지재단 천식의 분류를 위한 바이오마커 및 이의 용도
WO2025137230A1 (en) * 2023-12-20 2025-06-26 Areteia Therapeutics, Inc. Use of dexpramipexole for the treatment of inadequately controlled moderate to severe asthma
WO2025137498A1 (en) * 2023-12-20 2025-06-26 Areteia Therapeutics, Inc. Matrix tablets of dexpramipexole and methods of manufacturing and use thereof
WO2025240942A1 (en) * 2024-05-17 2025-11-20 Areteia Therapeutics, Inc. Use of dexpramipexole for the treatment of eosinophilic copd

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741490B2 (en) * 2004-03-19 2010-06-22 Dipharma S.P.A. Intermediates for the preparation of pramipexole
KR20100134702A (ko) * 2008-03-28 2010-12-23 글락소스미스클라인 엘엘씨 치료 방법
WO2013034173A1 (en) * 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
US9468630B2 (en) * 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
RS67279B1 (sr) * 2013-07-12 2025-10-31 Areteia Therapeutics Inc Lečenje povišenih nivoa eozinofila i/ili bazofila
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2017197360A1 (en) * 2016-05-13 2017-11-16 The Regents Of The University Of California Airway mucus impaction

Also Published As

Publication number Publication date
AU2021322255A1 (en) 2023-02-23
US20260021077A1 (en) 2026-01-22
US20240041840A1 (en) 2024-02-08
KR20230067604A (ko) 2023-05-16
US20220040154A1 (en) 2022-02-10
IL300357A (en) 2023-04-01
JP2023538278A (ja) 2023-09-07
CA3186844A1 (en) 2022-02-10
CN116419746A (zh) 2023-07-11
WO2022031956A1 (en) 2022-02-10
EP4192453A4 (en) 2024-11-13
US20240041841A1 (en) 2024-02-08
EP4192453A1 (en) 2023-06-14
AU2021322255A8 (en) 2023-03-30
MX2023001140A (es) 2023-05-18

Similar Documents

Publication Publication Date Title
MX2023001140A (es) Uso del dexpramipexol para el tratamiento de asma moderado a grave.
MX2021002321A (es) Nuevos metodos.
AR134835A2 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
PH12021553102A1 (en) Methods of treating fabry disease in patients having renal impairment
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
MX2021003681A (es) Composiciones y metodos para el tratamiento de desordenes inflamatorios.
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
MX2023000610A (es) Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
MX2022012001A (es) Tratamiento preventivo de la migra?a.
WO2020101790A3 (en) Methods of using a phenoxypropylamine compound to treat pain
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
EP4523750A3 (en) Methods of reducing cerebrovascular events in patients with fabry disease
EP4245366A3 (en) Migalastat for treating fabry patients having renal impairment
MX2024007010A (es) Pirimidinas y metodos para su uso.
ZA202201446B (en) Methods of treating multifocal cancer
MX2023013301A (es) Una pluralidad de particulas tasquinimod y su uso.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.